The Experts below are selected from a list of 2661 Experts worldwide ranked by ideXlab platform
S. Cakir - One of the best experts on this subject based on the ideXlab platform.
-
ocular signs symptoms and tear function tests of Papulopustular rosacea patients receiving azithromycin
Journal of The European Academy of Dermatology and Venereology, 2009Co-Authors: Özgür Bakar, Zeynep Demirçay, E. Toker, S. CakirAbstract:Abstract Background Tetracycline derivatives provide moderate benefit in the treatment of ocular rosacea. Recently, azithromycin has been found to be an effective alternative in the treatment of cutaneous Papulopustular rosacea. Objective We planned a study to evaluate the effects of azithromycin on ocular symptoms, signs and tear function tests of Papulopustular rosacea patients. Methods An open-labelled study was performed in a population of 20 Papulopustular rosacea patients. Results Eighteen subjects completed the trial. Significant improvement was seen in ocular symptoms, eyelid findings and conjunctival hyperaemia scores (P = 0.002, P < 0.0001, and P = 0.005, respectively). Therapeutic benefit was not observed in ocular surface staining scores. Baseline values of Schirmer test results were within normal limits. No significant side-effects were observed. Limitations The study population is limited to dermatology patients who had been referred to the ophthalmology clinic. Conclusion Azithromycin may be a new promising therapeutic alternative in ocular rosacea. Conflicts of interest None declared.
-
Ocular signs, symptoms and tear function tests of Papulopustular rosacea patients receiving azithromycin.
Journal of the European Academy of Dermatology and Venereology : JEADV, 2009Co-Authors: Özgür Bakar, Zeynep Demirçay, E. Toker, S. CakirAbstract:Abstract Background Tetracycline derivatives provide moderate benefit in the treatment of ocular rosacea. Recently, azithromycin has been found to be an effective alternative in the treatment of cutaneous Papulopustular rosacea. Objective We planned a study to evaluate the effects of azithromycin on ocular symptoms, signs and tear function tests of Papulopustular rosacea patients. Methods An open-labelled study was performed in a population of 20 Papulopustular rosacea patients. Results Eighteen subjects completed the trial. Significant improvement was seen in ocular symptoms, eyelid findings and conjunctival hyperaemia scores (P = 0.002, P
Chiel Cristiano F. Ebbelaar - One of the best experts on this subject based on the ideXlab platform.
-
Topical Ivermectin in the Treatment of Papulopustular Rosacea: A Systematic Review of Evidence and Clinical Guideline Recommendations
Dermatology and Therapy, 2018Co-Authors: Chiel Cristiano F. Ebbelaar, Aalt W. Venema, Maria R. DijkAbstract:Introduction Rosacea is a chronic inflammatory skin disease with different phenotypes. There is accumulating evidence that the commensal Demodex mite is linked to Papulopustular rosacea. Established treatment options, including topical metronidazole, azelaic acid, and tetracyclines, are thought to work through their anti-inflammatory effects. However, none of these therapies have been shown to be curative and are associated with frequent relapses. Therefore, new and improved treatment options are needed. Topical ivermectin 1.0% cream is a new option having both anti-inflammatory and acaricidal activity against Demodex mites which might pave the way to a more etiologic approach. Its use has now been widely adopted by clinical guidelines. The objective was to review the evidence and clinical guideline recommendations concerning ivermectin 1.0% cream in the treatment of Papulopustular rosacea. Methods A systematic review of both medical literature and clinical guideline recommendations was conducted. Numbers needed to treat (NNT) were calculated for relevant dichotomous outcomes (e.g., relapse rate and achieving full lesion clearance) to compare ivermectin with other established treatment options for rosacea. Results The search identified three randomized trials, three extension studies, and two meta-analyses. Ivermectin has only been tested in moderate-to-severe Papulopustular rosacea. Ivermectin is an effective treatment option for Papulopustular rosacea and seems to be more effective than metronidazole (NNT = 10.5) at 12 weeks of treatment. Although ivermectin was numerically more effective than metronidazole at week 36 in preventing relapse (NNT = 17.5), relapse after discontinuation of treatment in both groups was common with 62.7% and 68.4% of patients relapsing. Based on limited generalizability of available evidence, clinical guidelines have yielded different treatment algorithms and, in some areas, conflicting recommendations. Conclusion Topical ivermectin is an effective option in the treatment of Papulopustular rosacea. Although ivermectin seems to be more effective than topical metronidazole, with both treatment options about two-thirds of patient relapsed within 36 weeks after discontinuation of treatment. More research is needed to establish the clinical benefit of ivermectin’s acaricidal action in preventing relapse compared to other non-etiologic treatment approaches.
-
Topical Ivermectin in the Treatment of Papulopustular Rosacea : A Systematic Review of Evidence and Clinical Guideline Recommendations
Dermatology and therapy, 2018Co-Authors: Chiel Cristiano F. Ebbelaar, Aalt W. Venema, Maria R. Van DijkAbstract:Rosacea is a chronic inflammatory skin disease with different phenotypes. There is accumulating evidence that the commensal Demodex mite is linked to Papulopustular rosacea. Established treatment options, including topical metronidazole, azelaic acid, and tetracyclines, are thought to work through their anti-inflammatory effects. However, none of these therapies have been shown to be curative and are associated with frequent relapses. Therefore, new and improved treatment options are needed. Topical ivermectin 1.0% cream is a new option having both anti-inflammatory and acaricidal activity against Demodex mites which might pave the way to a more etiologic approach. Its use has now been widely adopted by clinical guidelines. The objective was to review the evidence and clinical guideline recommendations concerning ivermectin 1.0% cream in the treatment of Papulopustular rosacea. A systematic review of both medical literature and clinical guideline recommendations was conducted. Numbers needed to treat (NNT) were calculated for relevant dichotomous outcomes (e.g., relapse rate and achieving full lesion clearance) to compare ivermectin with other established treatment options for rosacea. The search identified three randomized trials, three extension studies, and two meta-analyses. Ivermectin has only been tested in moderate-to-severe Papulopustular rosacea. Ivermectin is an effective treatment option for Papulopustular rosacea and seems to be more effective than metronidazole (NNT = 10.5) at 12 weeks of treatment. Although ivermectin was numerically more effective than metronidazole at week 36 in preventing relapse (NNT = 17.5), relapse after discontinuation of treatment in both groups was common with 62.7% and 68.4% of patients relapsing. Based on limited generalizability of available evidence, clinical guidelines have yielded different treatment algorithms and, in some areas, conflicting recommendations. Topical ivermectin is an effective option in the treatment of Papulopustular rosacea. Although ivermectin seems to be more effective than topical metronidazole, with both treatment options about two-thirds of patient relapsed within 36 weeks after discontinuation of treatment. More research is needed to establish the clinical benefit of ivermectin’s acaricidal action in preventing relapse compared to other non-etiologic treatment approaches.
Ronald M. Gurge - One of the best experts on this subject based on the ideXlab platform.
-
treatment of Papulopustular rosacea with sodium sulfacetamide 10 sulfur 5 emollient foam
Journal of Drugs in Dermatology, 2009Co-Authors: Mark W. Trumbore, Jay A Goldstein, Ronald M. GurgeAbstract:Acne rosacea is a chronic cutaneous disorder affecting as many as 14 million Americans. Papulopustular rosacea is the classic form of rosacea characterized by papules, pustules, and erythema. The skin barrier deficiency and vascular hyperactivity characteristic of Papulopustular rosacea increase skin dryness and irritation, which can be further exacerbated by medications commonly used to treat rosacea. Sodium sulfacetamide 10%/sulfur 5% emollient foam (SSSE foam) is formulated for topical administration and is fragrance free and alcohol free. This nonrandomized, noncontrolled, open-label, prospective case series was designed to evaluate the efficacy and safety of a SSSE foam for the treatment of Papulopustular rosacea in 8 patients. Patients experienced clinically significant improvements in the severity of rosacea with a favorable safety profile, and reported of an improved quality of life. The high patient satisfaction ratings for SSSE foam suggest that the product may improve long-term compliance rates, with the potential to yield more favorable clinical outcomes.
-
Treatment of Papulopustular rosacea with sodium sulfacetamide 10%/sulfur 5% emollient foam.
Journal of drugs in dermatology : JDD, 2009Co-Authors: Mark W. Trumbore, Jay A Goldstein, Ronald M. GurgeAbstract:Acne rosacea is a chronic cutaneous disorder affecting as many as 14 million Americans. Papulopustular rosacea is the classic form of rosacea characterized by papules, pustules, and erythema. The skin barrier deficiency and vascular hyperactivity characteristic of Papulopustular rosacea increase skin dryness and irritation, which can be further exacerbated by medications commonly used to treat rosacea. Sodium sulfacetamide 10%/sulfur 5% emollient foam (SSSE foam) is formulated for topical administration and is fragrance free and alcohol free. This nonrandomized, noncontrolled, open-label, prospective case series was designed to evaluate the efficacy and safety of a SSSE foam for the treatment of Papulopustular rosacea in 8 patients. Patients experienced clinically significant improvements in the severity of rosacea with a favorable safety profile, and reported of an improved quality of life. The high patient satisfaction ratings for SSSE foam suggest that the product may improve long-term compliance rates, with the potential to yield more favorable clinical outcomes.
Özgür Bakar - One of the best experts on this subject based on the ideXlab platform.
-
ocular signs symptoms and tear function tests of Papulopustular rosacea patients receiving azithromycin
Journal of The European Academy of Dermatology and Venereology, 2009Co-Authors: Özgür Bakar, Zeynep Demirçay, E. Toker, S. CakirAbstract:Abstract Background Tetracycline derivatives provide moderate benefit in the treatment of ocular rosacea. Recently, azithromycin has been found to be an effective alternative in the treatment of cutaneous Papulopustular rosacea. Objective We planned a study to evaluate the effects of azithromycin on ocular symptoms, signs and tear function tests of Papulopustular rosacea patients. Methods An open-labelled study was performed in a population of 20 Papulopustular rosacea patients. Results Eighteen subjects completed the trial. Significant improvement was seen in ocular symptoms, eyelid findings and conjunctival hyperaemia scores (P = 0.002, P < 0.0001, and P = 0.005, respectively). Therapeutic benefit was not observed in ocular surface staining scores. Baseline values of Schirmer test results were within normal limits. No significant side-effects were observed. Limitations The study population is limited to dermatology patients who had been referred to the ophthalmology clinic. Conclusion Azithromycin may be a new promising therapeutic alternative in ocular rosacea. Conflicts of interest None declared.
-
Ocular signs, symptoms and tear function tests of Papulopustular rosacea patients receiving azithromycin.
Journal of the European Academy of Dermatology and Venereology : JEADV, 2009Co-Authors: Özgür Bakar, Zeynep Demirçay, E. Toker, S. CakirAbstract:Abstract Background Tetracycline derivatives provide moderate benefit in the treatment of ocular rosacea. Recently, azithromycin has been found to be an effective alternative in the treatment of cutaneous Papulopustular rosacea. Objective We planned a study to evaluate the effects of azithromycin on ocular symptoms, signs and tear function tests of Papulopustular rosacea patients. Methods An open-labelled study was performed in a population of 20 Papulopustular rosacea patients. Results Eighteen subjects completed the trial. Significant improvement was seen in ocular symptoms, eyelid findings and conjunctival hyperaemia scores (P = 0.002, P
Maria R. Van Dijk - One of the best experts on this subject based on the ideXlab platform.
-
Topical Ivermectin in the Treatment of Papulopustular Rosacea : A Systematic Review of Evidence and Clinical Guideline Recommendations
Dermatology and therapy, 2018Co-Authors: Chiel Cristiano F. Ebbelaar, Aalt W. Venema, Maria R. Van DijkAbstract:Rosacea is a chronic inflammatory skin disease with different phenotypes. There is accumulating evidence that the commensal Demodex mite is linked to Papulopustular rosacea. Established treatment options, including topical metronidazole, azelaic acid, and tetracyclines, are thought to work through their anti-inflammatory effects. However, none of these therapies have been shown to be curative and are associated with frequent relapses. Therefore, new and improved treatment options are needed. Topical ivermectin 1.0% cream is a new option having both anti-inflammatory and acaricidal activity against Demodex mites which might pave the way to a more etiologic approach. Its use has now been widely adopted by clinical guidelines. The objective was to review the evidence and clinical guideline recommendations concerning ivermectin 1.0% cream in the treatment of Papulopustular rosacea. A systematic review of both medical literature and clinical guideline recommendations was conducted. Numbers needed to treat (NNT) were calculated for relevant dichotomous outcomes (e.g., relapse rate and achieving full lesion clearance) to compare ivermectin with other established treatment options for rosacea. The search identified three randomized trials, three extension studies, and two meta-analyses. Ivermectin has only been tested in moderate-to-severe Papulopustular rosacea. Ivermectin is an effective treatment option for Papulopustular rosacea and seems to be more effective than metronidazole (NNT = 10.5) at 12 weeks of treatment. Although ivermectin was numerically more effective than metronidazole at week 36 in preventing relapse (NNT = 17.5), relapse after discontinuation of treatment in both groups was common with 62.7% and 68.4% of patients relapsing. Based on limited generalizability of available evidence, clinical guidelines have yielded different treatment algorithms and, in some areas, conflicting recommendations. Topical ivermectin is an effective option in the treatment of Papulopustular rosacea. Although ivermectin seems to be more effective than topical metronidazole, with both treatment options about two-thirds of patient relapsed within 36 weeks after discontinuation of treatment. More research is needed to establish the clinical benefit of ivermectin’s acaricidal action in preventing relapse compared to other non-etiologic treatment approaches.
